Nymox Pharmaceutical Corp (NYMX)

3.85
0.02 0.52
NASDAQ : Health Care
Prev Close 3.87
Open 3.86
Day Low/High 3.78 / 4.01
52 Wk Low/High 1.26 / 4.37
Volume 89.71K
Avg Volume 184.50K
Exchange NASDAQ
Shares Outstanding 52.37M
Market Cap 203.71M
EPS -0.30
P/E Ratio 11.79
Div & Yield N.A. (N.A)

Latest News

Commit To Purchase Nymox Pharmaceutical Corp At $3, Earn 25% Using Options

Investors considering a purchase of Nymox Pharmaceutical Corp shares, but cautious about paying the going market price of $4.11/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2019 put at the $3 strike, which has a bid at the time of this writing of 75 cents.

The Pockets of Speculative Action Have Dried Up

The Pockets of Speculative Action Have Dried Up

There simply aren't many compelling trades on my screen.

Jabbing a Needle in the Overinflated Nymox Prostate Drug Hype

Jabbing a Needle in the Overinflated Nymox Prostate Drug Hype

Nymox will not be successful in convincing the U.S. Food and Drug Administration (or its counterpart in Europe) to approve fexapotide to treat men with enlarged prostates.

These 5 Stocks Under $10 Could Make You a Lot of Money

These 5 Stocks Under $10 Could Make You a Lot of Money

Here's a technical look at how to trade several under-$10 stocks that are within range of triggering big breakouts.

Nymox Pharmaceuticals (NYMX) Stock Surges on Long-Term Prostate Drug Trial Success

Nymox Pharmaceuticals (NYMX) Stock Surges on Long-Term Prostate Drug Trial Success

Nymox Pharmaceuticals (NYMX) announced that a recent study on fexapotide, the company's lead drug for enlarged prostates and prostate cancer, was successful.

Nymox Pharmaceuticals (NYMX) Stock Surges on Prostate Drug Progress

Nymox Pharmaceuticals (NYMX) Stock Surges on Prostate Drug Progress

Nymox Pharmaceuticals (NYMX) is working to get its fexapotide drug approved and may partner with a larger company to help market the medication.

Nymox Announces Prostate Drug Progress

Nymox Announces Prostate Drug Progress

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Nymox Pharmaceutical Corporation

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against Nymox Pharmaceutical Corporation

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Nymox Pharmaceutical Corporation (NASDAQ: NYMX) resulting from allegations that Nymox...

Nymox Reports Long-Term Prostate Cancer Results In 7 Year Prospective Study Of 995 U.S. Middle-Aged And Elderly Men Without Cancer

Nymox Reports Long-Term Prostate Cancer Results In 7 Year Prospective Study Of 995 U.S. Middle-Aged And Elderly Men Without Cancer

Study Shows Major Reduction to Cumulative Incidence of Prostate Cancer in Study to 1.3%

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies have been scooping up shares of their own companies lately.